Prospective Grant of Exclusive License: Use of Lecithin-Cholesterol Acyltransferase (LCAT) To Reduce Accumulation of Cholesterol, 51652 [E7-17732]
Download as PDF
<![CDATA[
ebenthall on PRODPC61 with NOTICES
51652
Federal Register / Vol. 72, No. 174 / Monday, September 10, 2007 / Notices
Contact Person: Patrick K. Lai, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2215,
MSC 7812, Bethesda, MD 20892, 301–435–
1052, laip@csr.nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group, Biomaterials and Biointerfaces Study
Section.
Date: October 4, 2007.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel, Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Alexander Gubin, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5144,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group, Biochemistry and Biophysics
of Membranes Study Section.
Date: October 4–5, 2007.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Churchill Hotel, 1914 Connecticut
Avenue, NW., Washington, DC 20009.
Contact Person: Nuria E. Assa-Munt, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group,
Integrative Nutrition and Metabolic Processes
Study Section.
Date: October 4–5, 2007.
Time: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Oakland Marriott City Center, 1001
Broadway, Oakland, CA 94607.
Contact Person: Sooja K. Kim, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6182,
MSC 7892, Bethesda, MD 20892, (301) 435–
1780, kims@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group, Enabling Bioanalytical and
Biophysical Technologies Study Section.
Date: October 4, 2007.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle, NW., Washington, DC 20005.
Contact Person: Vonda K. Smith, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4148,
MSC 7806, Bethesda, MD 20892, 301–435–
1789, smithvo@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Shared
Instrumentation Grant Program: Surface
Plasmon Resonance (SPR) Instruments.
VerDate Aug<31>2005
15:27 Sep 07, 2007
Jkt 211001
Date: October 4, 2007.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Stephen M. Nigida, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4212,
MSC 7812, Bethesda, MD 20892, 301–435–
1222, nigidas@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 30, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4397 Filed 9–7–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Lecithin-Cholesterol
Acyltransferase (LCAT) To Reduce
Accumulation of Cholesterol
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license worldwide to practice the
invention embodied in United States
Patent Number 6,635,614 titled ‘‘Use of
Lecithin-Cholesterol Acyltransferase
(LCAT) to Reduce Accumulation of
Cholesterol,’’ referenced at DHHS as E–
007–1996/0–US–03, and corresponding
foreign patent application(s) and issued
patent(s), to AlphaCore Pharma, Inc.
having a place of business in the state
of Michigan. The field of use may be
limited to the following: FDA or similar
foreign body approved cardiovascular
and nephropathy therapeutic. The
United States of America is the assignee
of the patent rights in this invention.
The territory may be worldwide. This
announcement is the first notice to grant
an exclusive license to this technology.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
November 9, 2007 will be considered.
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Fatima Sayyid, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4521; Facsimile:
(301) 402–0220; e-mail:
Fatima.Sayyid@nih.hhs.gov.
ADDRESSES:
The
prospective exclusive license will be
royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUPPLEMENTARY INFORMATION:
Dated: August 29, 2007.
David R. Sadowski,
Deputy Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E7–17732 Filed 9–7–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
E:\FR\FM\10SEN1.SGM
10SEN1
]]>Agencies
[Federal Register Volume 72, Number 174 (Monday, September 10, 2007)]
[Notices]
[Page 51652]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-17732]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Lecithin-
Cholesterol Acyltransferase (LCAT) To Reduce Accumulation of
Cholesterol
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in
United States Patent Number 6,635,614 titled ``Use of Lecithin-
Cholesterol Acyltransferase (LCAT) to Reduce Accumulation of
Cholesterol,'' referenced at DHHS as E-007-1996/0-US-03, and
corresponding foreign patent application(s) and issued patent(s), to
AlphaCore Pharma, Inc. having a place of business in the state of
Michigan. The field of use may be limited to the following: FDA or
similar foreign body approved cardiovascular and nephropathy
therapeutic. The United States of America is the assignee of the patent
rights in this invention. The territory may be worldwide. This
announcement is the first notice to grant an exclusive license to this
technology.
DATES: Only written comments and/or application for a license, which
are received by the NIH Office of Technology Transfer on or before
November 9, 2007 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Fatima Sayyid, Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301) 435-4521; Facsimile: (301) 402-0220; e-mail:
Fatima.Sayyid@nih.hhs.gov.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty-bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within 60 days from the date of this published Notice,
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 29, 2007.
David R. Sadowski,
Deputy Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E7-17732 Filed 9-7-07; 8:45 am]
BILLING CODE 4140-01-P
